Literature DB >> 29777116

Genetic risk score of common genetic variants for impaired fasting glucose and newly diagnosed type 2 diabetes influences oxidative stress.

Minjoo Kim1, Minkyung Kim1, Limin Huang2,3, Sun Ha Jee4, Jong Ho Lee5,6,7.   

Abstract

We tested the hypothesis that the cumulative effects of common genetic variants related to elevated fasting glucose are collectively associated with oxidative stress. Using 25 single nucleotide polymorphisms (SNPs), a weighted genetic risk score (wGRS) was constructed by summing nine risk alleles based on nominal significance and a consistent effect direction in 1,395 controls and 718 patients with impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes. All the participants were divided into the following three groups: low-wGRS, middle-wGRS, and high-wGRS groups. Among the nine SNPs, five SNPs were significantly associated with IFG and type 2 diabetes in this Korean population. wGRS was significantly associated with increased IFG and newly diagnosed type 2 diabetes (p = 6.83 × 10-14, odds ratio = 1.839) after adjusting for confounding factors. Among the IFG and type 2 diabetes patients, the fasting serum glucose and HbA1c levels were significantly higher in the high-wGRS group than in the other groups. The urinary 8-epi-PGF2α and malondialdehyde concentrations were significantly higher in the high-wGRS group than in the other groups. Moreover, general population-level instrumental variable estimation (using wGRS as an instrument) strengthened the causal effect regarding the largely adverse influence of high levels of fasting serum glucose on markers of oxidative stress in the Korean population. Thus, the combination of common genetic variants with small effects on IFG and newly diagnosed type 2 diabetes are significantly associated with oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29777116      PMCID: PMC5959868          DOI: 10.1038/s41598-018-26106-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Oxidative stress has been reported as a contributing factor for the development of type 2 diabetes, diabetic complications and cardiovascular diseases[1]. Increased oxidative stress is associated with insulin resistance (IR), dyslipidemia, β-cell dysfunction, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and, ultimately, type 2 diabetes. Isoprostanes, which are derived from polyunsaturated fatty acids, are the most valuable biomarkers of oxidative stress and lipid peroxidation in biological systems[2]. Isoprostane assays measure the urinary levels of F2-isoprostanes, which become elevated in response to arachidonic acid peroxidation. Among these products, 8-epi-prostaglandin F2α (8-epi-PGF2α) is particularly important because it is the best-studied F2-isoprostane. According to previous studies, 8-epi-PGF2α is a predictor of glycemic control and oxidation status in patients with type 2 diabetes[3]. In addition, 8-epi-PGF2α is a reliable marker of IGT[4]. The genetic risk score (GRS) represents an integrative analytical approach for type 2 diabetes risk prediction that can be used efficiently and effectively to construct genome-wide risk measures based on the findings of genome-wide association studies (GWAS)[5-7]. Recent genetic risk assessment studies of type 2 diabetes have evaluated the predictive value of cumulative genetic scores[8,9]. The further development and improvement of a multi-single nucleotide polymorphism (SNP) GRS have led to better disease prediction and prevention in an independent ethnic population. We assessed the likelihood that currently available genetic information could be used to enhance disease prediction by constructing a GRS selected from 35 susceptibility variants for elevated fasting glucose[10] to test the hypothesis that the cumulative effects of these common genetic variants of IFG and type 2 diabetes are associated with oxidative stress. To strengthen this study, we also performed a Mendelian randomization analysis to investigate the causal effects of fasting serum glucose on markers of oxidative stress.

Results

The IFG and newly diagnosed type 2 diabetes patients (n = 718) included a significantly higher proportion of males who were older and heavier than the normal fasting glucose (NFG) controls (n = 1,395). The IFG and type 2 diabetes patients also exhibited significantly higher systolic and diastolic blood pressure (BP), triglyceride levels, fasting serum glucose levels, homeostatic model assessment of IR (HOMA-IR) scores, and hemoglobin A1c (HbA1c) levels than the controls. In addition, the subjects with IFG and newly diagnosed type 2 diabetes presented higher levels of urinary 8-epi-PGF2α and plasma malondialdehyde (MDA) than the controls (Table 1). The allelic frequencies of the 25 SNPs are shown in Table 2.
Table 1

Clinical characteristics of the study participants.

NFG (n = 1,395)IFG and type 2 diabetes (n = 718)p-valuep′-value
Sex (male/female)482/913374/344<0.001
Age (year)48.0 ± 0.3152.8 ± 0.40<0.001
BMI (kg/g)23.7 ± 0.0825.0 ± 0.11<0.001
Waist-to-hip ratio0.88 ± 0.000.90 ± 0.00<0.0010.368
Systolic BP (mmHg)119.6 ± 0.41126.8 ± 0.60<0.001<0.001
Diastolic BP (mmHg)75.2 ± 0.3079.0 ± 0.40<0.0010.013
Triglyceride (mg/dL)§118.1 ± 1.90144.3 ± 3.34<0.0010.001
Total cholesterol (mg/dL)§197.3 ± 0.95199.3 ± 1.380.3140.458
HDL cholesterol (mg/dL)§54.2 ± 0.3550.6 ± 0.50<0.0010.068
LDL cholesterol (mg/dL)§119.9 ± 0.86121.6 ± 1.280.4180.304
Fasting serum glucose (mg/dL)§86.9 ± 0.20118.4 ± 0.97<0.001<0.001
Insulin (μIU/dL)§9.09 ± 0.119.68 ± 0.240.3010.674
HOMA-IR§1.96 ± 0.032.85 ± 0.08<0.001<0.001
HbA1c (%)§5.68 ± 0.026.52 ± 0.05<0.001<0.001
8-epi-PGF (pg/mg creatinine)§1497.3 ± 24.01761.4 ± 35.5<0.001<0.001
Malondialdehyde (nmol/mL)§8.21 ± 0.0611.8 ± 0.24<0.001<0.001

Mean ± SE. Tested via logarithmic transformation. The p-value was derived from an independent t-test between two groups. The p′-value was derived from an independent t-test between two groups after adjusting for age, sex, and BMI.

Table 2

Association of 25 SNP loci with IFG and type 2 diabetes in a Korean population.

SNPNearby geneaRisk allelebRAF (case/control)UnadjustedAdjustedc
p-valueOR (95% CI)p-valueOR (95% CI)
rs340874 PROX1 C0.654/0.3700.9911.001 (0.878–1.140)0.9571.004 (0.874–1.153)
rs1260326 GCKR C0.487/0.4200.0000281.331 (1.155–1.488)0.0000091.356 (1.185–1.550)
rs11708067 ADCY5 A0.999/0.9970.1844.090 (0.511–32.730)0.1434.970 (0.582–42.415)
rs7756992 CDKAL1 G0.580/0.5610.2281.082 (0.952–1.229)0.0821.128 (0.985–1.291)
rs9368222 CDKAL1 A0.510/0.4850.1301.103 (0.972–1.251)0.0601.137 (0.995–1.300)
rs7747752 CDKAL1 C0.560/0.5410.2341.080 (0.951–1.226)0.0891.124 (0.982–1.285)
rs2191349 DGKB T0.700/0.6660.0231.171 (1.022–1.342)0.0111.207 (1.045–1.394)
rs1799884 GCK T0.208/0.1750.0091.237 (1.055–1.450)0.0271.209 (1.022–1.430)
rs3757840 GCK T0.619/0.5960.1491.101 (0.966–1.254)0.3561.067 (0.930–1.224)
rs4607517 GCK A0.246/0.2130.0141.204 (1.038–1.398)0.0451.175 (1.004–1.375)
rs11558471 SLC30A8 A0.627/0.5810.0041.211 (1.064–1.378)0.0021.240 (1.082–1.422)
rs7034200 GLIS3 A0.427/0.4080.2331.081 (0.951–1.228)0.2161.089 (0.951–1.247)
rs10811661 CDKN2A/B T0.606/0.5370.0000171.325 (1.166–1.507)0.0000101.358 (1.186–1.555)
rs4506565 TCF7L2 T0.031/0.0260.2941.221 (0.841–1.774)0.2411.268 (0.853–1.886)
rs7903146 TCF7L2 T0.035/0.0280.1971.265 (0.885–1.808)0.1191.353 (0.925–1.977)
rs12243326 TCF7L2 C0.003/0.0020.8601.117 (0.327–3.823)0.9680.972 (0.240–3.938)
rs11603334 ARAP1 G0.947/0.9400.3241.149 (0.872–1.515)0.6011.081 (0.807–1.447)
rs1387153 MTNR1B T0.466/0.4140.0011.236 (1.088–1.403)0.0001091.304 (1.140–1.492)
rs2166706 MTNR1B C0.475/0.4180.000391.258 (1.108–1.429)0.0000411.326 (1.159–1.517)
rs10830963 MTNR1B G0.482/0.4320.0021.224 (1.078–1.389)0.0000891.309 (1.144–1.497)
rs2293941 PDX1 A0.458/0.4760.2690.931 (0.820–1.057)0.2090.918 (0.803–1.049)
rs17271305 FAM148B/VPS13C/C2CD4A/B G0.158/0.1790.1180.865 (0.720–1.068)0.0760.840 (0.693–1.018)
rs4502156 FAM148B/VPS13C/C2CD4A/B T0.460/0.4370.1631.094 (0.964–1.242)0.1081.116 (0.976–1.276)
rs11071657 FAM148B/VPS13C/C2CD4A/B A0.658/0.6540.7681.020 (0.893–1.166)0.8961.009 (0.877–1.162)
rs10423928 GIPR A0.214/0.1980.2201.102 (0.994–1.288)0.2081.111 (0.943–1.309)
wGRS2.4364E-121.712 (1.473–1.990)6.8265E-141.839 (1.568–2.157)

The results of logistic regression analysis are shown.

OR, odds ratio; 95% CI, 95% confidence interval; wGRS, weighted genetic risk score.

aInformation in the original report is shown.

bRisk allele reported in previous reports.

cAdjusted for age, sex, and BMI.

wGRS was calculated including SNPs with nominal significance (p < 0.05).

Clinical characteristics of the study participants. Mean ± SE. Tested via logarithmic transformation. The p-value was derived from an independent t-test between two groups. The p′-value was derived from an independent t-test between two groups after adjusting for age, sex, and BMI. Association of 25 SNP loci with IFG and type 2 diabetes in a Korean population. The results of logistic regression analysis are shown. OR, odds ratio; 95% CI, 95% confidence interval; wGRS, weighted genetic risk score. aInformation in the original report is shown. bRisk allele reported in previous reports. cAdjusted for age, sex, and BMI. wGRS was calculated including SNPs with nominal significance (p < 0.05).

Association of each SNP with IFG and newly diagnosed type 2 diabetes

Using 25 SNPs from 15 loci, a weighted genetic risk score (wGRS) was constructed using nine association signals based on nominal significance and a consistent effect direction in a Korean population (Table 2). Five SNPs (GCKR rs1260326, CDKN2A/B rs10811661, MTNR1B rs1387153, rs2166706, and rs10830963) were significantly associated with IFG and type 2 diabetes (p = 9.0 × 10−6, 1.0 × 10−5, 1.09 × 10−4, 4.1 × 10−5, and 8.9 × 10−5, respectively) after adjusting for age, sex, and body mass index (BMI), and rs1260326 in GCKR exhibited the strongest association in the Korean sample. Additionally, rs2191349 in DGKB, rs1799884 and rs4607517 in GCK, and rs11558471 in SLC30A8 were nominally associated with IFG and type 2 diabetes (p = 0.011, 0.027, 0.045, and 0.002, respectively) after adjusting for age, sex, and BMI. Moreover, wGRS was significantly associated with increased IFG and newly diagnosed type 2 diabetes [p = 6.83 × 10−14, odds ratio (OR) per risk allele = 1.839, 95% confidence interval (CI) = 1.568–2.157] after adjusting for age, sex, and BMI (Table 2). According to the weighted tertile analysis, an increased number of risk alleles were associated with an increased OR for IFG and type 2 diabetes risk (Supplementary Figure S1).

Associations between wGRS and clinical characteristics

The IFG and type 2 diabetes patients exhibited a significantly higher wGRS than the NFG controls (1.93 ± 0.02 vs. 1.73 ± 0.02, p < 0.001) both before and after adjusting for age, sex, and BMI. Among the total study participants, wGRS was positively correlated with fasting serum glucose (r = 0.177, p < 0.001), HbA1c (r = 0.169, p < 0.001), HOMA-IR (r = 0.078, p < 0.001), 8-epi-PGF2α (r = 0.101, p < 0.001), and MDA (r = 0.134, p < 0.001). In the NFG controls, wGRS was positively correlated with fasting serum glucose (r = 0.126, p < 0.001). In the IFG and type 2 diabetes patients, HbA1c (r = 0.153, p = 0.004), HOMA-IR (r = 0.087, p = 0.023), 8-epi-PGF2α (r = 0.197, p < 0.001), and MDA (r = 0.231, p < 0.001) showed significant positive correlations with wGRS, and fasting serum glucose tended to be correlated with wGRS (r = 0.072, p = 0.055).

Investigation of the combined effects of wGRS on clinical features and oxidative stress

All the participants were divided into the following three approximately equally sized strata according to the wGRS, as described in Supplementary Table S1: low-wGRS, middle-wGRS, and high-wGRS groups. The characteristics of the IFG and type 2 diabetes patients in the three groups are shown in Table 3. The fasting serum glucose and HbA1c levels of the high-wGRS group were significantly higher than those of the low- and middle-wGRS groups. The HOMA-IR score was also significantly higher in the high-wGRS group than in the low-wGRS group. The urinary 8-epi-PGF2α and plasma MDA concentrations recorded in the IFG and type 2 diabetes patients in the three groups are shown in Fig. 1. The urinary 8-epi-PGF2α and plasma MDA levels were significantly higher in the high-wGRS group than in the low- and middle-wGRS groups. The characteristics of the NFG control subjects in the three groups are shown in Supplementary Table S2. The fasting serum glucose level in the high-wGRS group was significantly higher than that in the low-wGRS group. Among the total study participants, the fasting serum glucose, HbA1c, HOMA-IR, urinary 8-epi-PGF2α, and plasma MDA concentrations were significantly different between the different wGRS groups (Supplementary Table S3).
Table 3

Characteristics of the IFG and type 2 diabetes groups subdivided by the wGRS into three groups.

Low wGRS (n = 183)Middle wGRS (n = 227)High wGRS (n = 308)p-value
Age (year)53.0 ± 0.8852.8 ± 0.6652.6 ± 0.590.928
BMI (kg/m2)25.1 ± 0.2224.9 ± 0.2125.1 ± 0.170.744
Waist-to-hip ratio0.91 ± 0.000.90 ± 0.000.90 ± 0.000.367
Fasting serum glucose (mg/dL)§116.4 ± 2.10b116.7 ± 1.74b120.7 ± 1.37a0.011
Insulin (μIU/dL)§8.80 ± 0.319.57 ± 0.3610.3 ± 0.450.082
HbA1c (%)§6.37 ± 0.08b6.38 ± 0.09b6.73 ± 0.08a<0.001
HOMA-IR§2.52 ± 0.10b2.73 ± 0.11a,b3.13 ± 0.17a0.008

Mean ± SE. Tested via logarithmic transformation. The p-value was derived from a one-way ANOVA among the three groups. All letters indicating p < 0.05 were derived from Bonferroni’s post hoc test. Comparisons without a significant difference are indicated by the same letter, and significant differences are indicated by different letters.

Figure 1

Differences in 8-epi-GPF2α and malondialdehyde concentrations among the three groups of IFG and type 2 diabetes patients. Mean ± SE. ∮Tested via logarithmic transformation. One-way ANOVA was performed to calculate p-values. All letters indicating p < 0.05 were derived from Bonferroni’s post hoc test. Comparisons without a significant difference are indicated by the same letter, and significant differences are indicated by different letters.

Characteristics of the IFG and type 2 diabetes groups subdivided by the wGRS into three groups. Mean ± SE. Tested via logarithmic transformation. The p-value was derived from a one-way ANOVA among the three groups. All letters indicating p < 0.05 were derived from Bonferroni’s post hoc test. Comparisons without a significant difference are indicated by the same letter, and significant differences are indicated by different letters. Differences in 8-epi-GPF2α and malondialdehyde concentrations among the three groups of IFG and type 2 diabetes patients. Mean ± SE. ∮Tested via logarithmic transformation. One-way ANOVA was performed to calculate p-values. All letters indicating p < 0.05 were derived from Bonferroni’s post hoc test. Comparisons without a significant difference are indicated by the same letter, and significant differences are indicated by different letters.

Causal estimates from a Mendelian randomization analysis

The causal effects of fasting serum glucose on markers of oxidative stress were inferred through instrumental variable (IV) estimation techniques. The corresponding causal relationships were also assessed based on the association of wGRS with markers of oxidative stress (Supplementary Table S4). General population-level causal effects were assessed as IV estimates, where wGRS was used as an IV in the total study participants (Supplementary Table S5). As a result, one unit of fasting serum glucose (mg/dL) was associated with higher levels of oxidative stress markers, including urinary 8-epi-PGF2α and plasma MDA (all p < 0.001).

Association between specific SNPs and markers of oxidative stress

Based on the results shown in Table 2, we performed a multiple regression analysis to determine the direct contributors to urinary 8-epi-PGF2α and plasma MDA. rs2191349 (standardized β = 0.067, p = 0.004) and rs10811661 (standardized β = 0.061, p = 0.008) were merged as significant direct contributors to urinary 8-epi-PGF2α, and rs4607517, rs11558471, rs1387153, rs2166706, and rs10830963 tended to contribute to the association with urinary 8-epi-PGF2α (Supplementary Table S6). In addition, all nine SNPs emerged as direct contributors to plasma MDA, except that rs2191349 only presented a tendency to contribute to the association (Supplementary Table S6).

Discussion

In the present study, we examined nine susceptibility SNPs for IFG and newly diagnosed type 2 diabetes in a Korean population and constructed a wGRS to evaluate the influence of this genetic information on oxidative stress. The aggregation of common genetic variants influencing IFG and newly diagnosed type 2 diabetes plays a significant role in oxidative stress, despite having only small effects on glucose levels individually. wGRS was shown to be associated with the level of urinary 8-epi-PGF2α, which is the most reliable biomarker of lipid peroxidation and oxidative stress[11]. The urinary 8-epi-PGF2α levels were significantly higher in the high-wGRS group than in the low- and middle-wGRS groups of subjects with IFG and newly diagnosed type 2 diabetes. Moreover, general population-level IV estimation (using wGRS as an instrument) strengthened the causal effect regarding the largely adverse influence of high levels of fasting serum glucose on markers of oxidative stress in the Korean population. A highly significant correlation between blood glucose and urinary 8-epi-PGF2α has been previously reported, suggesting that glycemic control is related to the determinants of lipid peroxidation[12]. Similarly, enhanced formation and release of 8-epi-PGF2α by porcine vascular smooth muscle cells cultured under hyperglycemic conditions have been observed[13]. In the present study, the subjects with a high wGRS presented significantly higher serum glucose levels and HOMA-IR than those with a low wGRS in both the control and IFG and type 2 diabetes groups. Furthermore, the patients with IFG and newly diagnosed type 2 diabetes exhibited higher concentrations of urinary 8-epi-PGF2α and plasma MDA, which is a lipid peroxidation biomarker[1]. Moreover, compared with the subjects in the low- and middle-wGRS groups, significantly higher concentrations of urinary 8-epi-PGF2α and plasma MDA were observed in the IFG and newly diagnosed type 2 diabetes patients with a high wGRS. Thus, the higher fasting serum glucose and HOMA-IR observed in the subjects with high wGRS might be explained by elevated oxidative stress levels. Previous studies have demonstrated that oxidative stress plays the major role in IR pathogenesis[14,15]. There are several well-accepted mechanisms through which oxidative stress induces IR, including the activation of serine/threonine phosphorylation, disturbance of the cellular redistribution of insulin signaling components, decreased GLUT4 gene transcription, and alteration of mitochondrial activity[16]. Indeed, further support is provided by studies showing that IR can be ameliorated by antioxidant treatment[17,18]. In the current study, the IFG and type 2 diabetes patients showed steady increases in fasting serum glucose, insulin, HbA1c, and HOMA-IR across the wGRS groups. In addition, all these glucose-related markers were positively correlated with wGRS in the IFG and type 2 diabetes patients. In a previous study, Go et al.[19] confirmed the cumulative incidence rates of type 2 diabetes according to the quartile-based GRS; moreover, fasting plasma glucose and HbA1c steadily increased across the quartile-based GRS groups, which was consistent with the present study. In contrast to the IFG and type 2 diabetes patients, the NFG controls only showed a gradual increase in fasting serum glucose across the wGRS groups, which was additionally positively correlated with wGRS. Since wGRS was constructed using diabetes-related SNPs, fasting serum glucose and such glucose-related markers were positively correlated with wGRS. The high-wGRS group presented a higher potential risk probability for IFG and type 2 diabetes than the low-wGRS group because the high wGRS was constructed using the number of risk alleles with significantly high ORs. Therefore, the presence of a number of diabetes-related risk alleles could have more adverse effects on the risk of IFG and type 2 diabetes. Polygenic risk scores have recently generated much interest for assessing the explanatory power of risk variants in the clinical management and prevention of type 2 diabetes[20]. However, currently available genetic information can only be used for predicting the development of type 2 diabetes, and the detailed relationship between GRS and the clinical features of type 2 diabetes is unclear. In the present study, we selected nine genetic variants associated with elevated fasting serum glucose levels in the Korean population and constructed a wGRS of IFG for type 2 diabetes development to evaluate the possibility that currently available genetic information can be translated into clinical practice. The constructed GRS (wGRS) showed a much stronger association with IFG and newly diagnosed type 2 diabetes than with any individual SNP. wGRS was also associated with the fasting serum glucose levels, HbA1c levels, and HOMA-IR score in the IFG and newly diagnosed type 2 diabetes patients. Additionally, wGRS was strongly and significantly associated with the concentrations of urinary 8-epi-PGF2α and plasma MDA in the IFG and newly diagnosed type 2 diabetes patients. Indeed, the causal relationship between fasting serum glucose and markers of oxidative stress was confirmed in the present study when wGRS was used as an IV. Thus, the combined effects of numerous common variants associated with slight effects on elevated fasting serum glucose are associated with the risk of oxidative stress. In a recent study, both rs1260326 and rs780094 in GCKR were shown to be functional variants associated with type 2 diabetes and metabolic syndrome in a European population[21]. GCKR, which is a glucokinase regulatory protein produced in hepatocytes, binds glucokinase (GCK) and is involved in glucose metabolism[22]. Vaxillaire et al. showed that the GCK −30A allele is a true risk factor for the development of both IFG and type 2 diabetes, suggesting that this allele has a significant impact on β-cell function impairment[23], which is consistent with our findings regarding rs1799884 in GCK. In the present study, only rs1260326 was detected on the Korean chip (K-CHIP) and was markedly associated with the risk of IFG and type 2 diabetes. CDKN2A/B, the cyclin-dependent kinase inhibitor 2 A/B gene, impacts diabetes risk across various ethnicities and geographical locations via β-cell mass and proliferation[24]. MTNR1B, a melatonin receptor gene, is a common variant associated with an increased risk of future type 2 diabetes and impaired early insulin secretion[25]. DGKB, the diacylglycerol kinase βgene, which regulates the intracellular concentration of the second messenger diacylglycerol, was also recently associated with fasting glucose and type 2 diabetes risk[26,27]. A previous functional study of SLC30A8 suggested that reduced zinc transport increases type 2 diabetes risk[28,29]. Oxidative stress plays a crucial role in the pathophysiology of type 2 diabetes and has been observed to be higher in type 2 diabetes patients than healthy controls[30]. The higher expression of the nine established SNPs observed under diabetic conditions in the present study might be governed by higher oxidative stress in diabetics. The first established gene/SNP in the current study, GCKR, which is associated with insulin-like growth factor-binding protein 1 (IGFBP1) levels, inhibits a glucokinase responsible for key functions such as glucose homeostasis and the conversion of glucose in pancreatic β-cells and liver hepatocytes[31]. The functional rs1260326 missense variant in GCKR, which is associated with decreased serum IGFBP1 and an increased risk of type 2 diabetes[31]. Oxidative stress, leading to reduced mammalian target of rapamycin (mTOR) signaling, may play a role in the development of IR[32]. Because IGFBP1 expression is strongly regulated by insulin, it serves as an excellent marker of IR in type 2 diabetes patients. Second, intracellular hyperglycemia promotes abnormal diacylglycerol (DAG) accumulation which induce the activation of protein kinase C (PKC). DAG is converted to phosphatidic acid (PA) by diacylglycerol kinase (DGK), and enhanced DGK activity leads to a reduction in excess DAG accumulation induced by high glucose. Atsumi et al.[33] revealed that oxidative stress induced by high glucose can cause inhibition of DGK, possibly through redox modification of DGK. Based on a previous study, the T allele of rs2191349 near DGKB could lead to increased DGK activity, resulting in an excessive reduction of DAG levels, induced by hyperglycemic conditions. Third, possession of common risk alleles at the SLC30A8 locus, encoding the β-cell granule zinc transporter, may affect Zn2+ concentrations and, thus, susceptibility to oxidative stress. Zinc is known for its antioxidative properties and has been extensively studied as a possible treatment option for diabetic patients[34,35]. Zinc supplementation was found to lower fasting glucose levels in carriers of the common type 2 diabetes risk allele at rs11558471[36]. Fourth, Kong et al.[24] emphasized the roles of CDKN2A/B products and related proteins in the regulation of β-cell mass, proliferation, and insulin secretory function, in addition to roles in other metabolic tissues. Furthermore, a relationship between CDKN2A/B and oxidative stress has been reported, which is highly correlated with the hypermethylation of CDKN2A/B[37]. Last, melatonin receptors have been found throughout the body in many tissues and it has been shown that melatonin inhibits insulin secretion by pancreatic β-cells. Melatonin treatment improves BP, the lipid profile, and markers of oxidative stress in patients with metabolic syndrome[38]. The presence of copper ions could stimulate antioxidative stress mechanisms, including the synthesis of melatonin and its receptor. However, these mechanisms also likely include the activation of oxidative stress-related genes[39]. Taken together, the data indicate that the risk allele of MTNR1B is associated with a reduced antioxidative stress reaction due to a decrease in copper ions, which are involved in the synthesis of melatonin and its receptor. Therefore, melatonin cannot inhibit oxidation reactions catalyzed by reactive oxygen species scavengers, thus increasing fasting serum glucose as well as lipid peroxidation[40]. The present study was the first to predict IFG and type 2 diabetes using a GRS based on the concentrations of 8-epi-PGF2α and MDA, which are hallmarks of the intermediate phenotype of oxidative stress. In interpreting these findings, the typical limitations of cross-sectional observational studies should be considered, and these findings are indicative of the evaluated associations rather than prospective predictions. Additionally, we specifically focused on a representative group from the Korean population; thus, these results may not be generalizable to other ethnic groups. It could be more powerful to re-evaluate the nine identified SNPs in a replication cohort; therefore, a future investigation is warranted to define the causal variants within these loci to dissect their role in oxidative stress, which is a contributing factor for the development of IFG and type 2 diabetes. Despite these limitations, the present results show that the cumulative effects of common genetic variants associated with increased fasting serum glucose are also associated with oxidative stress, such as increases in the urinary 8-epi-PGF2α and plasma MDA concentrations. The causal relationship between fasting serum glucose and markers of oxidative stress was confirmed through Mendelian randomization analysis. Therefore, this study indicates that a higher fasting serum glucose level could be an exact adverse effector of oxidative stress. As knowledge of genetic variation increases, preclinical genetic screening tools might enhance the prediction and prevention of clinical events.

Methods

Study population

In total, 2,113 study participants with NFG, IFG, and newly diagnosed type 2 diabetes between the ages of 20 and 86 years were recruited from the Health Service Center (HSC) during routine checkups at the National Health Insurance Corporation Ilsan Hospital in Goyang, Korea (January 2010–March 2015). Based on the data screened from the HSC, subjects presenting with IFG and type 2 diabetes were referred to the Department of Family Medicine or Internal Medicine, and their health and glucose profiles were then re-assessed. The diagnosis of diabetes or IFG was based on the fasting serum glucose levels (≥126 mg/dL or 100–125 mg/dL, respectively). The exclusion criteria included a current diagnosis and/or history of cardiovascular disease, liver disease, renal disease, pancreatitis, or cancer and the regular use of any medication. All the study participants provided written informed consent, and the Institutional Review Board of Yonsei University and the National Health Insurance Corporation of Ilsan Hospital approved the study protocol, which complied with the Declaration of Helsinki.

SNP selection and genotyping

Based on a GWAS, 50 SNPs were established at type 2 diabetes loci showing the strongest associations with glycemic traits[10]. We selected 35 established SNPs associated with glycemic traits, particularly fasting glucose, including rs340874 near PROX1[26]; rs1260326 and rs780094 near GCKR[26,41]; rs11708067 and rs11717195 near ADCY5[26,41]; rs7651090 near IGF2BP2[42]; rs7708285 near ZBED3[42]; rs936822, rs7756992, and rs7747752 near CDKAL1[42-44]; rs17762454 near SSAR1/RREB1[42]; rs2191349 near DGKB[26]; rs1799884, rs6975024, rs4607517, and rs3757840 near GCK[26,42,43,45,46]; rs11558471 near SLC30A8[26,47]; rs7034200 near GLIS3[26]; rs10811661 near CDKN2A/B[42]; rs3829109 near DNLZ[42]; rs4506565, rs7903146, and rs12243326 near TCF77 L2[26,41,42,47]; rs11603334 near ARAP1[42,47,48]; rs1387153, rs10830963, and rs2166706 near MTNR1B[26,43,46,49-51]; rs116193319 and rs2293941 near PDX1[42,48]; rs17271305, rs4502156, and rs11071657 near FAM148B/VPS13C/C2CD4A/B[26,41,43,47]; and rs10423928, rs2302593, and rs11671664 near GIPR[41,42]. Genotyping was performed using an Axiom® 2.0 Reagent Kit (Affymetrix Axiom® 2.0 Assay User Guide; Affymetrix, Santa Clara, CA, USA), and the genotype data were produced using the K-CHIP, which is available through the K-CHIP consortium. The K-CHIP was designed by the Center for Genome Science at the Korea National Institute of Health (4845–301, 3000–3031). The detailed procedure was described in a previous report[52]. Ten fasting glucose-related SNPs were not included in the K-CHIP; therefore, 25 SNPs were used for the subsequent analysis.

GRS construction

Among the 25 SNPs, we constructed a wGRS using nine SNPs showing nominal significance (p < 0.05) and a consistent effect direction in the Korean population. Based on Bonferroni’s threshold (p < 0.002, 0.05 divided by 25), five SNPs remained after multiple testing. To maximize statistical power, all the SNPs with a nominal p-value <0.05 were included in the following risk score analysis. The estimate was analyzed by performing a logistic regression of the association between the number of risk alleles and the IFG and type 2 diabetes status. The wGRS was calculated by multiplying each estimated β-coefficient by the number of corresponding risk alleles (0, 1, or 2).

Laboratory assessments

All anthropometry information has been previously described[53]. The participants’ weights and heights were measured to calculate their BMI (kilograms per square meter). The waist circumstance was measured to calculate the waist-to-hip ratio, and BP was assessed using an automatic BP monitor after a resting period of at least 20 min. After overnight fasting for at least 12 h, venous blood samples and urine samples were collected and stored at −80 °C and −20 °C, respectively. To assess the lipid profile, serum triglyceride, total cholesterol, and high-density lipoprotein (HDL) cholesterol levels were measured using commercial kits and an auto analyzer, and low-density lipoprotein (LDL) cholesterol levels were calculated using the Friedewald formula. The fasting serum glucose level and glucose-related markers, including insulin, HOMA-IR score, and HbA1c, were also measured. These laboratory assessments, including the lipid profile and glucose-related markers, have previously been described in detail[53]. Commercial assay kits were used to detect the urinary 8-epi-PGF2α and plasma malondialdehyde (MDA) concentrations[54].

Statistical analysis

The statistical analyses, which included an independent t-test to compare two groups, determination of Pearson’s correlation coefficient to examine the relationships between wGRS and traits (variables), one-way ANOVA to compare three groups according to wGRS, a logistic regression to calculate the OR and 95% CI, a chi-square test to determine the frequency of the risk allele, and a general linear model UNIANOVA to adjust for confounding factors, were performed using SPSS v.24.0 (IBM/SPSS, Chicago, IL, USA). Skewed variables were log transformed, and all tests were considered statistically significant at a two-tailed p-value < 0.05. The causal effect of fasting serum glucose on markers of oxidative stress was analyzed under an IV regression with a two-stage least squares estimation method for all the subjects using wGRS as an instrument. In the first stage, the linear regression of fasting serum glucose on wGRS was calculated. In the second stage, the predicted values of fasting serum glucose were used as covariates in the linear regression analysis with markers of oxidative stress as the dependent variable. All the regressions were performed after adjustment for age, sex, and BMI. Supplementary information
  53 in total

1.  Association of glycosylated hemoglobin with the gene encoding CDKAL1 in the Korean Association Resource (KARE) study.

Authors:  Jihye Ryu; Chaeyoung Lee
Journal:  Hum Mutat       Date:  2012-02-20       Impact factor: 4.878

2.  Zinc transporter gene expression and glycemic control in post-menopausal women with Type 2 diabetes mellitus.

Authors:  Meika Foster; Anna Chu; Peter Petocz; Samir Samman
Journal:  J Trace Elem Med Biol       Date:  2014-08-02       Impact factor: 3.849

3.  The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma.

Authors:  Minjoo Kim; Minkyung Kim; Ji Yun Han; Sang-Hyun Lee; Sun Ha Jee; Jong Ho Lee
Journal:  Diab Vasc Dis Res       Date:  2016-12-21       Impact factor: 3.291

4.  Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors.

Authors:  R Natarajan; L Lanting; N Gonzales; J Nadler
Journal:  Am J Physiol       Date:  1996-07

Review 5.  Oxidative stress, insulin signaling, and diabetes.

Authors:  Justin L Rains; Sushil K Jain
Journal:  Free Radic Biol Med       Date:  2010-12-13       Impact factor: 7.376

6.  Insulin regulation of hepatic insulin-like growth factor-binding protein-1 (IGFBP-1) gene expression and mammalian target of rapamycin (mTOR) signalling is impaired by the presence of hydrogen peroxide.

Authors:  Satish Patel; Jeroen Van Der Kaay; Calum Sutherland
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

7.  Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.

Authors:  Valeriya Lyssenko; Cecilia L F Nagorny; Michael R Erdos; Nils Wierup; Anna Jonsson; Peter Spégel; Marco Bugliani; Richa Saxena; Malin Fex; Nicolo Pulizzi; Bo Isomaa; Tiinamaija Tuomi; Peter Nilsson; Johanna Kuusisto; Jaakko Tuomilehto; Michael Boehnke; David Altshuler; Frank Sundler; Johan G Eriksson; Anne U Jackson; Markku Laakso; Piero Marchetti; Richard M Watanabe; Hindrik Mulder; Leif Groop
Journal:  Nat Genet       Date:  2008-12-07       Impact factor: 38.330

8.  Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways.

Authors:  Nicole Soranzo; Serena Sanna; Eleanor Wheeler; Christian Gieger; Dörte Radke; Josée Dupuis; Nabila Bouatia-Naji; Claudia Langenberg; Inga Prokopenko; Elliot Stolerman; Manjinder S Sandhu; Matthew M Heeney; Joseph M Devaney; Muredach P Reilly; Sally L Ricketts; Alexandre F R Stewart; Benjamin F Voight; Christina Willenborg; Benjamin Wright; David Altshuler; Dan Arking; Beverley Balkau; Daniel Barnes; Eric Boerwinkle; Bernhard Böhm; Amélie Bonnefond; Lori L Bonnycastle; Dorret I Boomsma; Stefan R Bornstein; Yvonne Böttcher; Suzannah Bumpstead; Mary Susan Burnett-Miller; Harry Campbell; Antonio Cao; John Chambers; Robert Clark; Francis S Collins; Josef Coresh; Eco J C de Geus; Mariano Dei; Panos Deloukas; Angela Döring; Josephine M Egan; Roberto Elosua; Luigi Ferrucci; Nita Forouhi; Caroline S Fox; Christopher Franklin; Maria Grazia Franzosi; Sophie Gallina; Anuj Goel; Jürgen Graessler; Harald Grallert; Andreas Greinacher; David Hadley; Alistair Hall; Anders Hamsten; Caroline Hayward; Simon Heath; Christian Herder; Georg Homuth; Jouke-Jan Hottenga; Rachel Hunter-Merrill; Thomas Illig; Anne U Jackson; Antti Jula; Marcus Kleber; Christopher W Knouff; Augustine Kong; Jaspal Kooner; Anna Köttgen; Peter Kovacs; Knut Krohn; Brigitte Kühnel; Johanna Kuusisto; Markku Laakso; Mark Lathrop; Cécile Lecoeur; Man Li; Mingyao Li; Ruth J F Loos; Jian'an Luan; Valeriya Lyssenko; Reedik Mägi; Patrik K E Magnusson; Anders Mälarstig; Massimo Mangino; María Teresa Martínez-Larrad; Winfried März; Wendy L McArdle; Ruth McPherson; Christa Meisinger; Thomas Meitinger; Olle Melander; Karen L Mohlke; Vincent E Mooser; Mario A Morken; Narisu Narisu; David M Nathan; Matthias Nauck; Chris O'Donnell; Konrad Oexle; Nazario Olla; James S Pankow; Felicity Payne; John F Peden; Nancy L Pedersen; Leena Peltonen; Markus Perola; Ozren Polasek; Eleonora Porcu; Daniel J Rader; Wolfgang Rathmann; Samuli Ripatti; Ghislain Rocheleau; Michael Roden; Igor Rudan; Veikko Salomaa; Richa Saxena; David Schlessinger; Heribert Schunkert; Peter Schwarz; Udo Seedorf; Elizabeth Selvin; Manuel Serrano-Ríos; Peter Shrader; Angela Silveira; David Siscovick; Kjioung Song; Timothy D Spector; Kari Stefansson; Valgerdur Steinthorsdottir; David P Strachan; Rona Strawbridge; Michael Stumvoll; Ida Surakka; Amy J Swift; Toshiko Tanaka; Alexander Teumer; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Anke Tönjes; Gianluca Usala; Veronique Vitart; Henry Völzke; Henri Wallaschofski; Dawn M Waterworth; Hugh Watkins; H-Erich Wichmann; Sarah H Wild; Gonneke Willemsen; Gordon H Williams; James F Wilson; Juliane Winkelmann; Alan F Wright; Carina Zabena; Jing Hua Zhao; Stephen E Epstein; Jeanette Erdmann; Hakon H Hakonarson; Sekar Kathiresan; Kay-Tee Khaw; Robert Roberts; Nilesh J Samani; Mark D Fleming; Robert Sladek; Gonçalo Abecasis; Michael Boehnke; Philippe Froguel; Leif Groop; Mark I McCarthy; W H Linda Kao; Jose C Florez; Manuela Uda; Nicholas J Wareham; Inês Barroso; James B Meigs
Journal:  Diabetes       Date:  2010-09-21       Impact factor: 9.461

9.  Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis.

Authors:  Stavroula Kanoni; Jennifer A Nettleton; Marie-France Hivert; Zheng Ye; Frank J A van Rooij; Dmitry Shungin; Emily Sonestedt; Julius S Ngwa; Mary K Wojczynski; Rozenn N Lemaitre; Stefan Gustafsson; Jennifer S Anderson; Toshiko Tanaka; George Hindy; Georgia Saylor; Frida Renstrom; Amanda J Bennett; Cornelia M van Duijn; Jose C Florez; Caroline S Fox; Albert Hofman; Ron C Hoogeveen; Denise K Houston; Frank B Hu; Paul F Jacques; Ingegerd Johansson; Lars Lind; Yongmei Liu; Nicola McKeown; Jose Ordovas; James S Pankow; Eric J G Sijbrands; Ann-Christine Syvänen; André G Uitterlinden; Mary Yannakoulia; M Carola Zillikens; Nick J Wareham; Inga Prokopenko; Stefania Bandinelli; Nita G Forouhi; L Adrienne Cupples; Ruth J Loos; Goran Hallmans; Josée Dupuis; Claudia Langenberg; Luigi Ferrucci; Stephen B Kritchevsky; Mark I McCarthy; Erik Ingelsson; Ingrid B Borecki; Jacqueline C M Witteman; Marju Orho-Melander; David S Siscovick; James B Meigs; Paul W Franks; George V Dedoussis
Journal:  Diabetes       Date:  2011-08-01       Impact factor: 9.461

10.  Polygenic type 2 diabetes prediction at the limit of common variant detection.

Authors:  Jason L Vassy; Marie-France Hivert; Bianca Porneala; Marco Dauriz; Jose C Florez; Josée Dupuis; David S Siscovick; Myriam Fornage; Laura J Rasmussen-Torvik; Claude Bouchard; James B Meigs
Journal:  Diabetes       Date:  2014-02-11       Impact factor: 9.337

View more
  6 in total

1.  Variation in resistance to oxidative stress in Oregon-(R)R-flare and Canton-S strains of Drosophila melanogaster.

Authors:  Santiago Cristobal Sigrist-Flores; Laura Castañeda-Partida; Myriam Campos-Aguilar; Luis Felipe Santos-Cruz; Aranza Miranda-Gutierrez; I A Gallardo-Ortíz; R Villalobos-Molina; Irma Elena Dueñas-García; María Eugenia Heres-Pulido; Elías Piedra-Ibarra; Víctor Hugo Rosales-García; Rafael Jimenez-Flores; Alberto Ponciano-Gómez
Journal:  Toxicol Res (Camb)       Date:  2021-07-22       Impact factor: 2.680

2.  Early Prediction for Prediabetes and Type 2 Diabetes Using the Genetic Risk Score and Oxidative Stress Score.

Authors:  Ximei Huang; Youngmin Han; Kyunghye Jang; Minjoo Kim
Journal:  Antioxidants (Basel)       Date:  2022-06-17

3.  Thai CV Risk Score and Primary Prevention in Impaired Fasting Plasma Glucose or Diabetes Mellitus versus Normoglycemia in Patients with Metabolic Syndrome.

Authors:  Duangjai Duangrithi; Ruja Wattanasermkit; Sudarat Rungwijee; Natthanicha Khunsom
Journal:  Int J Prev Med       Date:  2020-09-05

4.  A Genetic Risk Score Improves the Prediction of Type 2 Diabetes Mellitus in Mexican Youths but Has Lower Predictive Utility Compared With Non-Genetic Factors.

Authors:  América Liliana Miranda-Lora; Jenny Vilchis-Gil; Daniel B Juárez-Comboni; Miguel Cruz; Miguel Klünder-Klünder
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

5.  Genome-wide association study of metabolic syndrome in Korean populations.

Authors:  Seung-Won Oh; Jong-Eun Lee; Eunsoon Shin; Hyuktae Kwon; Eun Kyung Choe; Su-Yeon Choi; Hwanseok Rhee; Seung Ho Choi
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

6.  MYLK and PTGS1 Genetic Variations Associated with Osteoporosis and Benign Breast Tumors in Korean Women.

Authors:  Hye-Won Cho; Hyun-Seok Jin; Yong-Bin Eom
Journal:  Genes (Basel)       Date:  2021-03-06       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.